Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
Public ClinicalTrials.gov record NCT00262522. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-label, Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With NRTIs in Antiretroviral Naive HIV-1 Infected Subjects
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study was to compare the safety and tolerability of the to-be-marketed lopinavir/ritonavir (LPV/r) tablet formulation with the marketed soft gel capsule (SGC) formulation and to compare the safety, tolerability, and antiviral activity of once daily (QD) and twice daily (BID) dosing of the LPV/r tablet formulation in combination with select nucleoside reverse transcriptase inhibitors (NRTIs) in patients who have not previously received antiretroviral treatment.
Study identification
- NCT ID
- NCT00262522
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 664 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2005 (Type not available)
- Primary completion
- Jul 2008 (Actual)
- Completion
- Jul 2008 (Actual)
- Last update posted
- Feb 6, 2012
2005 – 2008
United States locations
- U.S. sites
- 30
- U.S. states
- 13
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 823 | Phoenix | Arizona | 85006 | — |
| Site Reference ID/Investigator# 846 | Phoenix | Arizona | 85012 | — |
| Site Reference ID/Investigator# 851 | Beverly Hills | California | 90211 | — |
| Site Reference ID/Investigator# 872 | Fountain Valley | California | 92708 | — |
| Site Reference ID/Investigator# 826 | Long Beach | California | 90813 | — |
| Site Reference ID/Investigator# 876 | Newport Beach | California | 92663 | — |
| Site Reference ID/Investigator# 875 | Washington D.C. | District of Columbia | 20037 | — |
| Site Reference ID/Investigator# 870 | Atlantis | Florida | 33462 | — |
| Site Reference ID/Investigator# 844 | Fort Lauderdale | Florida | 33311 | — |
| Site Reference ID/Investigator# 874 | Miami | Florida | 33136 | — |
| Site Reference ID/Investigator# 1153 | Orlando | Florida | 32803 | — |
| Site Reference ID/Investigator# 827 | Orlando | Florida | 32803 | — |
| Site Reference ID/Investigator# 783 | Plantation | Florida | 33317 | — |
| Site Reference ID/Investigator# 877 | Port Saint Lucie | Florida | 34952 | — |
| Site Reference ID/Investigator# 845 | Safety Harbor | Florida | 34695 | — |
| Site Reference ID/Investigator# 849 | Sarasota | Florida | 34243 | — |
| Site Reference ID/Investigator# 825 | Tampa | Florida | 33614 | — |
| Site Reference ID/Investigator# 848 | Atlanta | Georgia | 30309 | — |
| Site Reference ID/Investigator# 873 | Macon | Georgia | 31201 | — |
| Site Reference ID/Investigator# 1154 | Chicago | Illinois | 60612 | — |
| Site Reference ID/Investigator# 824 | Chicago | Illinois | 60613 | — |
| Site Reference ID/Investigator# 792 | Wichita | Kansas | 67214 | — |
| Site Reference ID/Investigator# 1157 | Minneapolis | Minnesota | 55404 | — |
| Site Reference ID/Investigator# 871 | St Louis | Missouri | 63108 | — |
| Site Reference ID/Investigator# 2450 | Rochester | New York | 14620 | — |
| Site Reference ID/Investigator# 784 | Charlotte | North Carolina | 28209 | — |
| Site Reference ID/Investigator# 1155 | Dallas | Texas | 75208 | — |
| Site Reference ID/Investigator# 850 | Dallas | Texas | 75246 | — |
| Site Reference ID/Investigator# 843 | Houston | Texas | 77004 | — |
| Site Reference ID/Investigator# 1156 | Hampton | Virginia | 23666 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00262522, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00262522 live on ClinicalTrials.gov.